1524-88-5 Usage
Originator
Haelan ,Lilly ,UK ,1962
Uses
Different sources of media describe the Uses of 1524-88-5 differently. You can refer to the following data:
1. Flurandrenolide (Cordran, Cordran SP) is a synthetic fluorinated corticosteroid.
2. antiinflammatory; Glucocorticoid; antipsoriatic.
Indications
Flurandrenolide (Cordran, Cordran SP) is a synthetic fluorinated corticosteroid.
Brand name
Cordran (Oclassen); Cordran (Watson).
Therapeutic Function
Glucocorticoid, Antiinflammatory
Biological Functions
Corticosteroids influence all tissues of the body and produce numerous and varying effects in cells.
These steroids regulate carbohydrate, lipid, and protein biosynthesis and metabolism (glucocorticoid effects),
and they influence water and electrolyte balance (mineralocorticoid effects). Cortisol is the most potent
glucocorticoid secreted by the adrenal gland, and aldosterone is the most potent endogenous mineralocorticoid.
Both naturally occurring glucocorticoids and related, semisynthetic analogues can be evaluated in terms of their
ability to sustain life, to stimulate an increase in blood glucose concentrations and a deposition of liver
glycogen, to decrease circulating eosinophils, and to cause thymus involution in adrenalectomized
animals. In addition, corticosteroids can affect immune system functions, inflammatory responses,
and cell growth.
The primary physiologic function of glucocorticoids is to maintain blood glucose levels and, thus, ensure
glucose-dependent processes critical to life, particularly brain functions. Cortisol and related steroids
accomplish this by stimulating the formation of glucose, by diminishing glucose use by peripheral tissues, and
by promoting glycogen synthesis in the liver to increase carbohydrate stores for later release of glucose.
General Description
Flurandrenolide, 6α-fluoro-11β,21-dihydroxy-16α,17-[(1-methylethylidene)bis(oxy)]pregn-4-ene-3,20-dione, although available as a tape product,can stick to and remove damaged skin, so it should beavoided with vesicular or weeping dermatoses.
Mechanism of action
Glucocorticoid action is mediated through the glucocorticoid receptor, which is found primarily in the cytosol of
the cell when not bound to glucocorticoids. The GR is stabilized in the cytosol by complexation with
phosphorylated proteins, including a 90-kDa protein referred to as a heat shock protein 90. The steroid
molecule binds to the GR, resulting in a conformational change of the receptor to dissociate the other proteins
and initiate translocation of the steroid–receptor complex into the nucleus. The steroid–nuclear GR complex
interacts with particular HRE regions of the cellular DNA, referred to as glucocorticoid-responsive elements and
initiates transcription of the DNA sequence to produce mRNA. Finally, the elevated levels of mRNA lead to
increased protein synthesis in the endoplasmic reticulum. These proteins then mediate glucocorticoid effects on
carbohydrate, lipid, and protein metabolism. An alternative isoform of the GR has been identified. This isoform
of the receptor does not bind known glucocorticoids, and its function remains to be determined.
Clinical Use
Two major uses of glucocorticoids are in the treatment of rheumatoid diseases and allergic manifestations.
Their use in the treatment of severe asthma is well documented, as is the utility of glucocorticoids in sepsis and
acute respiratory distress syndrome. They are effective in the treatment of rheumatoid arthritis, acute
rheumatic fever, bursitis, spontaneous hypoglycemia in children, gout, rheumatoid carditis, sprue, allergy
(including contact dermatitis), and other conditions. The treatment of chronic rheumatic diseases and allergic
conditions with glucocorticoids is symptomatic and continuous. Symptoms return after withdrawal of the drug.
Side effects
Although side effects and toxicities vary with the drug and, sometimes, with the patient, facial mooning,
flushing, sweating, acne, thinning of the scalp hair, abdominal distention, and weight gain are observed with
most glucocorticoids. Protein depletion (with osteoporosis and spontaneous fractures), myopathy (with
weakness of muscles of the thighs, pelvis, and lower back), and aseptic necrosis of the hip and humerus are
other side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 1524-88-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,5,2 and 4 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1524-88:
(6*1)+(5*5)+(4*2)+(3*4)+(2*8)+(1*8)=75
75 % 10 = 5
So 1524-88-5 is a valid CAS Registry Number.
InChI:InChI=1/C24H33FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h7,13-14,16-17,19-20,26,28H,5-6,8-11H2,1-4H3/t13?,14?,16-,17-,19+,20?,22-,23-,24+/m0/s1
1524-88-5Relevant articles and documents
6α-fluoro- and 6α,9α-difluoro-11β,21-dihydroxy- 16α,17α- propylmethylene-dioxypregn-4-ene-3,20-dione: Synthesis and evaluation of activity and kinetics of their C-22 epimers
Thalen, B. Arne,Axelsson, Bengt I.,Andersson, Paul H.,Brattsand, Ralph L.,Nylander, Benkt,Wickstroem, Lars-Inge
, p. 37 - 43 (1998)
It is generally accepted that the anti-inflammatory, effect of glucocorticosteroids cannot be separated from their adverse effects at the receptor level. However, modification of the pharmacokinetics through structural alterations could provide steroids with a better therapeutic index than those currently used. Thus, new 16α, 17α-acetals between butyraldehyde and 6α-fluoro- or 6α, 9α-difluoro-16α-hydroxycortisol were synthesized and studied. Acetalization of the corresponding 16α, 17α-diols or transacetalization of their 16α, 17α-acetonides in dioxane produced mixtures of C-22 epimers, which were resolved by preparative chromatography. Alternatively, an efficient method was used to produce the 22R-epimer stereoselectively through performing the acetalization and transacetalization in a hydrocarbon with an inert material present. The C-22 configuration of (22R)-6α, 9α-difluoro-11β,21-dihydroxy-16α,17α- propylmethylenedioxypregn-4-ene-3,20-dione was unambiguously established by single crystal X-ray diffraction. The present compounds, especially the 22R- epimer just mentioned, bind to the rat thymus glucocorticoid receptor with high potency. The C-22 epimers of the 6α, 9α-difluoro derivatives showed a 10-fold higher biotransformation rate than the budesonide 22R-epimer when incubated with human liver S9 subcellular fraction. The high receptor affinity, in combination with the high biotransformation rate indicates that (22R)-6α,9α-difluoro-11β,21-dihydroxy-16α,17α-propylmethylenedioxypregn- 4-ene-3,20-dione may be an improved 16α, 17α-acetal glucocorticosteroid for therapy of inflammatory diseases, in which the mucous membranes are involved, such as those in the intestinal tract as well in the respiratory tract.
Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
-
, (2008/06/13)
Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
Smilagenin and its use
-
, (2008/06/13)
The invention discloses the use of a smilagenin in the treatment of cognitive disfunction and similar conditions. Methods of treatment, and pharmaceutical compositions are also disclosed.
